Alessio Cortellini, Consultant Medical Oncologist and Assistant Professor at Campus Bio-Medico University of Rome, shared a post on X:
“Very proud to share our paper in The Lancet Oncology.
Using the randomized PACIFIC trial, we provide the first evidence that microbiota-modifying medications may influence immunotherapy benefit in a curative-intent/early-stage setting.
Years of work, brilliantly led by Brunet Leon. Huge thanks to Derosa Lisa and her outstanding team for their invaluable collaboration!
The story is far from over, findings deserve further prospective and mechanistic research.”
Title: Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial
Authors: Leonardo Brunetti, Valentina Santo, David J. Pinato, Fabrizio Citarella, Sarah Orlando, Fabian Acker, Vittoria Colella, Biagio Ricciuti, Jarushka Naidoo, Amin Nassar, Heather A. Wakelee, Kazuki Takada, Abdul Rafeh Naqash, Marina C. Garassino, Carlo Greco, Sara Ramella, Francesco Pantano, Giuseppe Tonini, Bruno Vincenzi, Bryan Arlunno, Jordi Remon, Claudia Parisi, David Planchard, Benjamin Besse, Antoine Desilets, Bertrand Routy, Arielle Elkrief, Fabrice Barlesi, Lisa Derosa, Alessio Cortellini
Read the full article on The Lancet Oncology.
Other articles featuring Alessio Cortellini on OncoDaily.